Today: 18 July 2026
DroneShield (ASX:DRO) share price: set for Monday test after 7.5% Friday drop and pipeline reset
1 February 2026
2 mins read

DroneShield (ASX:DRO) share price: set for Monday test after 7.5% Friday drop and pipeline reset

Sydney, Feb 1, 2026, 17:42 AEDT — The market has closed.

  • DroneShield shares ended Friday at A$3.32, slipping 7.5%.
  • Since closing on Jan. 23, the stock has dropped roughly 26% following four consecutive days of declines.
  • Investors are focused on the A$2.09 billion pipeline alongside the release timing of audited FY2025 results.

DroneShield shares slipped 7.5% to finish Friday at A$3.32, putting the counter-drone company at a disadvantage as it enters the new week.

Since closing on Jan. 23, the stock has dropped roughly 25.7%, with steep daily losses piling up into the end of the month. Moves like this usually shake out short-term investors or attract new sellers.

Why it matters now: investors are weighing DroneShield’s recent quarterly report and its impact on deal conversions in 2026. For high-growth defense tech firms, a new contract announcement can shift sentiment sharply—but a weaker pipeline figure can do just as much damage.

DroneShield’s filings are crucial since its sales often come in fits and starts — a handful of big defence contracts can change a quarter’s picture entirely. Investors zero in on the “pipeline” of potential, unsigned deals and the actual cash received before the market kicks back into gear.

The company posted A$51.3 million in revenue for the quarter ended Dec. 31, a 94% jump from the previous year, alongside customer cash receipts of A$63.5 million. Operating cash flow swung to a positive A$7.7 million, compared with an A$8.9 million outflow a year earlier. It holds A$95.6 million in committed revenue for 2026, and cash and equivalents stood at A$210.4 million at quarter-end. The update highlighted contracts worth A$49.6 million with a European military client and A$25.3 million in Latin America. Audited FY2025 results are expected in February.

DroneShield reported its sales pipeline at A$2.09 billion in January, down from A$2.5 billion in October, according to an investor presentation released alongside the update. The company attributed the decline mainly to early-stage, low-probability projects that either stalled or were scaled back, as well as a stronger Australian dollar. It also emphasized that the pipeline is unweighted and doesn’t guarantee future sales.

A separate ASX filing on Thursday revealed the company applied to list 4.565 million new fully paid ordinary shares. These came from exercised options or converted securities. Even a relatively small uptick in supply can impact a stock already under pressure.

CEO Oleg Vornik said on this week’s earnings call that the company kicked off 2026 with “essentially AUD 100 million” in locked-in revenues already secured. He added they don’t offer guidance because “it would just be irresponsible” in such a “nascent industry.” Investing.com Nigeria

But the next move isn’t set in stone. Defence and security contracts often drag on, budgets shift, and pipelines get reshuffled — particularly when early-stage projects hang in the balance and might never actually close. Following a 26% drop in a single week, the price action alone could trigger further swings.

Shares resume trading Monday, Feb. 2, as investors look for new contract updates and signs that selling pressure might be easing. Attention now shifts to the company’s audited FY2025 results, expected to be released in February.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Viking Therapeutics slips 4.6%, keeps obesity trial valuation edge
    July 18, 2026, 1:15 PM EDT. Viking Therapeutics (NASDAQ:VKTX) fell 4.6% this week but continues to trade at an 86% cash-adjusted valuation premium over Structure Therapeutics (NASDAQ:GPCR). Viking's injectable obesity candidates are in Phase 3, supporting its clinical-stage premium amid higher expenses and a broader loss forecast for 2026. At March 31, Viking reported $603 million in cash, while Structure held $1.46 billion, providing funding through mid-2027 and late 2028, respectively. Analysts like William Blair's Andy Hsieh maintain a Buy rating. Second-quarter results, due July 29, will spotlight cash burn, R&D spending and study outcomes. According to Viking's CEO, the oral VK2735 candidate achieved encouraging efficacy, delivering notable weight loss over 13 weeks compared with placebo.
Imperial Brands share price slips as €900m bond terms land; buyback and dividend dates next for IMB
Previous Story

Imperial Brands share price slips as €900m bond terms land; buyback and dividend dates next for IMB

BAT share price: British American Tobacco stock heads into Monday with lawsuit cloud and results clock ticking
Next Story

BAT share price: British American Tobacco stock heads into Monday with lawsuit cloud and results clock ticking

Go toTop